Ten-year nodular sclerosis Hodgkin's disease and second malignancies.
Détails
ID Serval
serval:BIB_D4C438FB1C89
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Ten-year nodular sclerosis Hodgkin's disease and second malignancies.
Périodique
European Journal of Cancer and Clinical Oncology
ISSN
0277-5379 (Print)
ISSN-L
0277-5379
Statut éditorial
Publié
Date de publication
04/1989
Volume
25
Numéro
4
Pages
659-665
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Hodgkin's disease is one of the most curable cancers thanks to progress in radiotherapy and multi-drug chemotherapy regimens such as mechloretamine-vincristine-procarbazine-prednisone, best known as MOPP. However, long-term side-effects and treatment-induced second malignancies are of great concern. In our institution, 69 patients with nodular sclerosis Hodgkin's disease were treated over 10 years. Twenty-two per cent were stage I, 49% stage II, 23% stage III and 6% stage IV. Actuarial 10-year survival was 83% and actuarial relapse-free survival 61%. Six patients developed a second malignancy with a 10-year actuarial risk of 18%. All six cases occurred in the group treated with MOPP and extensive radiotherapy. Acute non-lymphoblastic leukemia occurred in three patients, preleukemia in two and non Hodgkin's lymphoma in one. In all of these patients, the results were quite poor. Overall survival was equally affected by Hodgkin's disease and by second malignancies. Since new multiple-drug chemotherapy regimens such as adriamycin-bleomycin-vinblastine-dacarbazine, known as ABVD, are equally effective and seem less likely to induce second hematologic malignancies, we suggest that MOPP should no longer be used as a first choice for the treatment of Hodgkin's disease, especially when in combination with radiation therapy.
Mots-clé
Adult, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Combined Modality Therapy, Female, Hodgkin Disease/drug therapy, Hodgkin Disease/radiotherapy, Humans, Male, Mechlorethamine/administration & dosage, Neoplasms, Multiple Primary/etiology, Prednisone/administration & dosage, Procarbazine/administration & dosage, Radiotherapy/adverse effects, Retrospective Studies, Vincristine/administration & dosage
Pubmed
Web of science
Création de la notice
24/01/2008 18:12
Dernière modification de la notice
20/08/2019 16:54